Shizuoka, Hamamatsu, Japan
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
Phase
3Span
277 weeksSponsor
Juntendo UniversityHamamatsu, Shizuoka
Recruiting
Hamamatsu, Shizuoka
Recruiting
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
Total study duration per participant will be up to 58 weeks, including a screening period of up to 4 weeks, a treatment period up to 52 weeks and a post-treatment follow-up period of 2 weeks.
Phase
2Span
212 weeksSponsor
SanofiHamamatsu, Shizuoka
Recruiting
Hamamatsu, Shizuoka
Recruiting
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Phase
3Span
397 weeksSponsor
PfizerHamamatsu, Shizuoka
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase
2/3Span
315 weeksSponsor
Janssen Research & Development, LLCHamamatsu
Recruiting
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Phase
3Span
226 weeksSponsor
UCB Biopharma SRLHamamatsu
Recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Phase
3Span
199 weeksSponsor
Janssen Research & Development, LLCHamamatsu
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Phase
3Span
201 weeksSponsor
Anthos Therapeutics, Inc.Hamamatsu
Recruiting
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Phase
3Span
340 weeksSponsor
Eli Lilly and CompanyHamamatsu, Shizuoka
Recruiting
1-10 of 33